Cardiovascular Risk Markers in Patients With Rheumatoid Arthritis: Effect of Rituximab Therapy.

Trial Profile

Cardiovascular Risk Markers in Patients With Rheumatoid Arthritis: Effect of Rituximab Therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2015

At a glance

  • Drugs Rituximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacodynamics
  • Acronyms RITUXANFMD
  • Most Recent Events

    • 25 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrial.gov record.
    • 20 Jun 2014 Planned End Date changed from 1 Jun 2014 to 1 Dec 2014 as reported by ClinicalTrial.gov record.
    • 16 Jan 2014 Planned End Date changed from 1 Dec 2013 to 1 Jun 2014 as reported by ClinicalTrial.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top